POMC and neoplasm: Among the functioning tumor patients (16), 7/16 presented growth hormone (GH) secreting tumors, 7/16 medically resistant prolactinomas (PRL), 1/16 thyroid-stimulating hormone (TSH) and 1/16 adrenocorticotrophic hormone (ACTH) secreting tumor.